<div id="readability-page-1"><p>DENTSPLY SIRONA ((XRAY)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Dentsply Sirona’s latest earnings call struck a cautiously constructive tone, pairing clear operational progress with equally visible near-term pressures. Management pointed to improving cash flow, cost cuts and a deepening innovation pipeline as proof the turnaround is gaining traction, but they were frank about declining constant-currency sales, margin compression and macro risks that will weigh on results before growth returns.</p> <h2>Revenue Holds Steady as Guidance Reaffirmed</h2> <p>Dentsply Sirona reported Q1 revenue of $880 million, essentially flat year over year on an as-reported basis but down 6.7% in constant currency, or 4.5% after one-time headwinds. Even so, management kept 2026 guidance intact, calling for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50, signaling confidence in its multi-year return-to-growth plan.</p> <h2>Stronger Cash Flow and Focused Deleveraging</h2> <p>Operating cash flow improved sharply to $40 million in Q1 from $7 million a year earlier, helping strengthen the balance sheet despite softer revenue. The company ended the quarter with $190 million in cash, net debt to EBITDA at 3.3x and retired roughly $79–$80 million of debt, underscoring a priority on deleveraging while funding its transformation.</p> <h2>Restructuring Delivers Early Cost Savings</h2> <p>The return-to-growth restructuring program is targeting $120 million in annual savings, and early benefits are already showing in the P&amp;L. Operating expenses fell by about $20 million in Q1 on a constant-currency basis, giving management more room to offset gross margin pressure and reinvest in growth initiatives without stretching the balance sheet.</p> <h2>Innovation Engine Accelerates With New Launches</h2> <p>Management highlighted a slate of new products, led by SmartView Detect, an AI diagnostic aid that boosted detection sensitivity by about 46% in clinical evaluation. The company also secured FDA clearance for a dental-dedicated MRI and launched the Reciproc Minima file system, the X-Smart Go cordless endomotor and expanded Sureti offerings, supported by higher R&amp;D spending year on year.</p> <h2> pockets of Growth Across Segments and Regions</h2> <p>Despite overall softness, specific franchises and geographies posted solid gains, offering investors some reassurance on underlying demand. Wellspect Healthcare grew 3.4% in constant currency, EMEA rose 4% and SureSmile logged 11% growth in EMEA, while parts of APAC and regional pieces of EDS delivered double-digit gains and U.S. demand for mills strengthened.</p> <h2>Distribution Expansion Builds Commercial Reach</h2> <p>The company leaned into channel expansion with four new distributor agreements year-to-date, including an expanded deal with Atlanta Dental Supply for its connected tech portfolio effective August 1. Early wins included Benco installing its first CEREC system under a new agreement ahead of schedule, suggesting that the broadened distribution network is already starting to translate into equipment placements.</p> <h2>Underlying Constant-Currency Sales Still Declining</h2> <p>Beneath flat reported revenue, the constant-currency picture showed a more challenging reality with Q1 sales down 6.7% year over year. Even after backing out the Byte impact and a tough comparison in treatment centers, the 4.5% constant-currency decline highlighted near-term demand softness that the turnaround program will have to overcome.</p> <h2>Margins Squeezed by Volume, Mix and Tariffs</h2> <p>Profitability took a notable hit as adjusted EBITDA margins contracted by 430 basis points and gross profit fell 560 basis points. Management blamed lower volumes, unfavorable sales mix and tariff headwinds for the margin compression, signaling that cost savings alone will not be enough until revenue stabilizes and price/mix improves.</p> <h2>Core Businesses Feel the Pressure</h2> <p>Several key segments posted declines, underscoring the breadth of the current slowdown and the work still ahead. OIS dropped 13.5% in constant currency (7.6% excluding Byte), EDS fell 7.2%, CTS slipped 2.9% with high-single-digit declines in equipment and instruments, implants declined high single digits globally and SureSmile saw a low single-digit overall decline driven by U.S. weakness.</p> <h2>Distributor Destocking Weighs on Equipment Demand</h2> <p>Channel dynamics remain a headwind, particularly for capital equipment, as U.S. distributor inventories in CAD/CAM and imaging stay below historical levels. Management said dealer destocking, especially in parts of Europe, contributed to softness in EDS and is likely to persist, delaying the timing of replenishment orders even where end-market demand is more stable.</p> <h2>Tariffs and Macro Risks Add to Uncertainty</h2> <p>Tariffs were a material drag on gross margin in the quarter and remain a visible risk factor in the near term, even as management expects some easing later this year. The company also flagged ongoing macro and geopolitical uncertainties, including exposure to the Middle East and Central Europe and pressures from freight and oil costs, which could further impact both cost structure and demand.</p> <h2>Inventory Sell-Through Headwind Still to Come</h2> <p>An additional drag is still in the pipeline as roughly $30 million of expected inventory sell-through under the new drop-ship model did not hit Q1 results. Management anticipates this headwind will materialize from late Q2 into the back half of the year, posing another temporary weight on reported sales as the company adjusts its distribution model.</p> <h2>Long Road to Full Benefits of Turnaround</h2> <p>Executives reiterated that the return-to-growth plan is a multi-year, roughly 24-month journey rather than a quick fix, with most of the meaningful benefits building into the second half of 2026. They expect the impact of restructuring, innovation and channel expansion to become much more apparent in 2027–2028, leaving investors to navigate execution and timing risk over the next several quarters.</p> <h2>Guidance and Outlook Emphasize Patience and Discipline</h2> <p>Management’s decision to maintain 2026 guidance for $3.5–$3.6 billion in sales and $1.40–$1.50 in adjusted EPS underlines their belief that current headwinds are manageable and largely transitory. They pointed to $120 million in targeted annual savings, about $20 million realized in Q1, an expected roughly 300 basis-point gross-margin lift into Q2–Q3 as tariffs ease and improved cash generation, while stressing a conservative, risk-aware stance given the macro backdrop.</p> <p>Dentsply Sirona’s earnings call painted a picture of a company in active repair mode, delivering tangible progress on cash flow, costs, innovation and distribution while confronting real demand and margin pressures. For investors, the message was clear: the balance of risks and opportunities is finely poised in the near term, but management is betting that disciplined execution over the next few years will ultimately restore growth and profitability.</p></div>

XRAY

<p>Dentsply Sirona's Q1 earnings call highlighted operational progress amid near-term challenges. Revenue remained flat at $880 million, with a 6.7% decline in constant currency. Management reaffirmed 2026 guidance of $3.5–$3.6 billion in net sales. Operating cash flow improved to $40 million, supporting debt reduction efforts. Despite some growth in specific segments, overall constant-currency sales fell, and adjusted EBITDA margins contracted due to lower volumes and unfavorable sales mix. Tariffs and macroeconomic uncertainties pose additional risks to profitability and demand.</p>

Dentsply Sirona Earnings Call Balances Progress and Pain